7th Mar 2016 07:00
7 March 2016
Premaitha Health plc
("Premaitha" or "the Company")
Appointment of Joint Broker
Manchester, UK: Premaitha Health plc (AIM: NIPT), the company enabling wide scale adoption of a safe, fast, accurate and complete CE Marked non-invasive prenatal screening system, announces that finnCap Ltd has been appointed as joint broker to the Company with immediate effect.
For more information, please contact:
Premaitha Health plc | Tel: +44 (0) 161 667 6865 |
Dr Stephen Little, Chief Executive Officer |
|
Joanne Cross, Head of Marketing |
|
| |
|
|
Cairn Financial Advisers LLP (Nomad) | Tel: +44 (0) 20 7148 7900 |
Liam Murray / Avi Robinson |
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) | Tel: +44 (0) 20 7886 2500 |
Robert Naylor (Corporate Finance) / Maisie Rose Atkinson (Sales) |
|
|
|
finnCap (Joint Broker) | Tel: +44 (0) 20 7220 0500 |
Adrian Hargrave / Scott Mathieson (Corporate Finance) Tony Quirke (Corporate Broking) |
|
|
|
Vigo Communications | Tel: +44 (0) 20 7830 9700 |
Ben Simons / Fiona Henson |
|
|
About Premaitha:
Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.
Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.
Unlike existing prenatal screening methods, due to its speed and high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures which carry a risk of miscarriage.
NIPT is an emerging, multi-billion dollar global market and Premaitha's complete CE Marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening solution in-house.
Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.
Related Shares:
YGEN.L